Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary obstruction. Its main purpose was to report mortality and stent failure at long term, which remained unknown. 

COMPARE TAVI: Resultados al año de un estudio aleatorizado que compara dos válvulas balón expandibles

Primary end point was long term mortality, while secondary end point was stent failure. This was a multicenter study including patients from 35 centers distributed along three continents. Patients with all kinds of stents or valves participated, in contexts of native aortic stenosis or valve-in-valve procedures, and with traditional or orthotropic chimney stenting.

Participant mean age was 80.9 years. 30.7% of the total procedures were done in native valves, 64.6% were TAV-in-SAV, and 4.7% TAV-in-TAV. Most cases (72.5%), received the classical chimney technique with a stent positioned as protection. 

Patients with established coronary artery obstruction presented significantly more adverse events, mainly death and cardiogenic shock, vs. those treated with coronary obstruction prevention strategies. 

Read also: CCANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx.

The absence of coronary protection was significantly associated with a combined end point of hospital mortality, acute myocardial infarction and cardiogenic shock (OR 8.36; CI95% 3.84-18.18; p≤0.001).

Among mortality predictors at 30 days, the most significant were the presence of established CAD (OR 10.02; p≤0.001) and lack of coronary protection (OR 7.11; p=0.002). On the other hand, long term mortality predictors were stage ≥2 kidney failure (OR 2.32; p=0.039) and access other than femoral. There were no predictors of stent failure. 

Read also: TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation.

Chimney stent failure was low (4%), with no significant differences in events according to coronary prevention strategy. At midterm follow-up, global mortality reached 22.4%.

Presented by Paolo Alberto del Sole at Top Late-Breaking Trials, PCR London Valves, November 24, 2024, London, GB.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...